Full-Time

Formulation and Filling Lead

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Global biopharmaceutical company focused on R&D

No salary listed

Senior, Expert

Pisa, Province of Pisa, Italy

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s / Master's degree in chemistry, pharmaceutical chemistry, biology, engineering
  • Knowledge of cGMP
  • Experience in sterility environment, filling of sterile under isolators.
  • Previous experience of at least three/five years in the pharmaceutical field as Formulation and Filling Lead
  • Previous experience of at least 10 years in the pharmaceutical/chemical sector in Manufacturing area.
  • Knowledge of the main leadership behaviors
  • Communication and presentation skills
  • Excellent knowledge of English and Italian
  • Availability of 5% of the time to travel
  • Knowledge of the Albumin formulation and sterile filling process
  • Ability to interpret and modify the production plan
  • Knowledge of MBR and Production SOPs
  • Orientation to results, always acting in accordance with Takeda PTRB
  • Ability to manage a team and changes
  • Ability to positively influence and motivate the team, communicating effectively and in alignment with business requirements, Safety, Quality and company objectives
  • Have an enterprising mindset, finding innovative ways to serve patients, build trust, reputation and business.
  • Ability to create a positive and collaborative environment that incentivizes the team to work together effectively.
  • Focused on priorities, lead the team on achieving goals with constant alignment.
  • Recognize the potential of people and take the time to develop skills to increase performance.
Responsibilities
  • Ensure compliance with EHS regulations in working hours during the activities leads and controls
  • Responsible for respecting the coverage of production volumes planned by the Supply Chain
  • Guarantee continuous improvement related to production aspects and team
  • Coordinate Production activities (Albumin Formulation and Filling) according to the reference
  • Organize the qualification operations of Production personnel (5%)
  • Participate in the management of the review of procedures, training, activities related to the opening and investigation of events, validations and Change Controls in Production (10%)
  • Meet the expected production targets in terms of process times, communicating any delays and modifying the production plan accordingly (15%)
  • Coordinate production personnel and plan their activities in order to comply with the production plan and carry out trainings; evaluate the performance of their own reports (15%)
  • Responsible for network interactions and global programs related to Albumin Production
  • Organize and plan all the production activities independently, based on the production plan
  • Manage the reporting staff independently, assessing their performance and ensuring proper training
  • Coordinate with the other reference functions in order to achieve the goal or solve problems
  • Investigate the issues occurred during the Albumin production process and decide the actions to be taken to solve them (such as communication to the higher level)
Desired Qualifications
  • Belonging to protected categories (Law No. 68/99) will be considered a preferential qualification.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline of 11 NMEs, aiming for up to 15 product launches by FY2024. Takeda's products are designed to meet the needs of healthcare providers, hospitals, and patients around the world. What sets Takeda apart from its competitors is its strong commitment to patient-centric values and environmental sustainability, recognizing the connection between human health and environmental health. The company's goal is to innovate and provide life-changing therapies while ensuring that patient needs are prioritized.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's collaboration with BridGene is worth up to $770 million.
  • The company is expanding its market presence in emerging Asian economies.
  • Takeda's focus on personalized medicine aligns with industry trends.

What critics are saying

  • Antitrust litigation over Amitiza could harm Takeda's reputation and finances.
  • A data breach incident poses significant cybersecurity and legal risks.
  • The telehealth market's rapid changes may affect Takeda's investment in American Well.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations.
  • Takeda has a robust pipeline with 11 NMEs and aims for 15 launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

ETF Daily News
May 11th, 2025
Tudor Investment Corp ET AL Decreases Stock Holdings in American Well Co. (NYSE:AMWL)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in American Well in the fourth quarter worth about $564,000.

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.